Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | FDPS | P14324 | 3/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103933 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL102248 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL199423 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL200435 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL198808 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL199832 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL100485 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL102506 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL101339 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 | |
| SCHEMBL102172 | 1.00 | LMNA (0.52) | LMNADNM1TSHRTHRBOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023085299-A1 | CATIONIC LIPID | 武田薬品工業株式会社 | 2023-05-19 | — | — | WO | disclosed |
| CN-116113657-A | Alkoxylated polymeric N- (hydroxyalkyl) amines as wetting agents and as components of defoamer compositions | 巴斯夫欧洲公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-113200958-B | Phthalate ester organic photoelectric compound and preparation method and application thereof | 国家纳米科学中心 | 2022-08-05 | — | — | CN | disclosed |
| CN-113200958-A | Phthalate ester organic photoelectric compound and preparation method and application thereof | 国家纳米科学中心 | 2021-08-03 | — | — | CN | disclosed |
| US-20210102237-A1 | MEANS AND METHODS FOR NUCLEIC ACID TARGET DETECTION | BIOTANGENTS LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
| EP-3759245-A1 | MEANS AND METHODS FOR NUCLEIC ACID TARGET DETECTION | Biotangents Limited (GB) | 2021-01-06 | — | — | EP | disclosed |
| US-20140329014-A1 | Composition and Method for Treating Wood | DANIP PTY LTD (AU) | 2014-11-06 | — | — | US | disclosed |
| US-8481736-B2 | Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof | BASF SE (DE) | 2013-07-09 | — | — | US | disclosed |
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-7005261-B1 | Method for detecting nucleic acid target sequences involving in vitro transcription from an RNA polymerase promoter | BRITISH BIOCELL INTERNATIONAL LIMITED (GB) | 2006-02-28 | — | — | US | disclosed |
| US-6391593-B1 | DETECTING PREFERENTIAL NUCLEOTIDE SEQUENCES; OBTAIN SAMPLES, INCUBATE WITH PROBES, AMPLIFY NUCLEOTIDE SEQUENCES, DETECT AMPLIFIED NUCLEOTIDE SEQUENCES | CYTOCELL LIMITED (GB) | 2002-05-21 | — | — | US | disclosed |
| EP-1200627-A1 | METHOD FOR DETECTING NUCLEIC ACID TARGET SEQUENCES INVOLVING IN VITRO TRANSCRIPTION FROM AN RNA POLYMERASE PROMOTER | Cytocell Limited (GB) | 2002-05-02 | — | — | EP | disclosed |
| CN-1284070-A | Alicyclic acylated heterocyclic derivatives | SANKYO CO (JP) | 2001-02-14 | — | — | CN | disclosed |
| WO-2001009377-A1 | METHOD FOR DETECTING NUCLEIC ACID TARGET SEQUENCES INVOLVING IN VITRO TRANSCRIPTION FROM AN RNA POLYMERASE PROMOTER | CYTOCELL LIMITED (GB) | 2001-02-08 | — | — | WO | disclosed |
| EP-1051515-A2 | MODIFIED NUCLEIC ACID PROBES AND USES THEREOF | Cytocell Limited (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037806-A2 | MODIFIED NUCLEIC ACID PROBES AND USES THEREOF | CYTOCELL LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
| EP-0492930-A2 | Transdermal delivery of dobutamine | ELI LILLY AND COMPANY (US) | 1992-07-01 | — | — | EP | disclosed |
| US-4980371-A | TREATMENT OF HIV INFECTIONS/LEUKEMIA; ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS | MERRELL DOW PHARMACEUTICALS (US) | 1990-12-25 | — | — | US | disclosed |
| EP-0374886-A2 | Antiretroviral furan ketones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329014-A1 | Composition and Method for Treating Wood | SGMS2, SGMS1, C1S | LMNA 236/4885DNM1 3359/4885TSHR 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.